Caring Together: Carefull to Partner with the Alzheimer's Association to Protect Families
NEW YORK--(BUSINESS WIRE)-- Carefull, the first financial safety platform built specifically for older adults and their families, is proud to support the Alzheimer's Association in raising awareness of the financial warning signs of cognitive decline and equipping families with tools to take early, protective action to prevent fraud and mistakes. Carefull is proud to support the care, services and research initiatives of the Alzheimer's Association. The Alzheimer's Association will provide information and resources aimed at helping families affected by dementia navigate financial challenges on Carefull's website.
"Alzheimer's disease comes with a daily financial reality for families, and we are beyond proud to be working with the Alzheimer's Association to ensure financial safety is part of the cognitive health conversation"
Share
Designed to detect early behavioral signals and safeguard day-to-day finances, Carefull offers both a window into the early stages of cognitive change and a system to help preserve the financial independence and wellbeing of those affected. Carefull partners with financial institutions nationwide to bring these protections directly to the families they serve.
Each year, more than 900,000 Americans develop Alzheimer's disease, with 7.2 million people aged 65 and older currently living with the condition. Behind each diagnosis is a network of loved ones offering critical support— nearly 12 million unpaid caregivers in the U.S. provide more than 19 billion hours of care annually for individuals with Alzheimer's or other dementias.
'We're committed to working with organizations that share our mission to protect and support older adults and their families. This effort is about helping families see what's happening sooner and act with confidence,' said Todd Rovak, Co-Founder of Carefull. 'Alzheimer's disease comes with a daily financial reality for families, and we are beyond proud to be working with the Alzheimer's Association to ensure financial safety is part of the cognitive health conversation.'
Growing evidence shows that financial missteps—like missed bill payments, rising credit card debt, or unusual generosity—can signal early cognitive decline, including Alzheimer's. Research from institutions such as Johns Hopkins, Georgetown, and the National Institute on Aging suggests these behaviors may surface up to six years before a clinical diagnosis. Identifying these financial warning signs offers a powerful opportunity for early intervention and support.
Carefull turns this insight into action, offering families and caregivers proactive tools that can detect behavioral changes in financial activity. Through real-time alerts, Carefull ScamCheck, trusted contact infrastructure, and an expert and empathetic care team, Carefull provides early signals that allow families to act before small issues become life-altering crises, and deploy a system to safeguard someone who may become vulnerable to inbound financial scams.
Long before a diagnosis, subtle financial changes like missed bills, unusual spending, or increased vulnerability to scams, can be among the first signs that something is wrong. Early detection of Alzheimer's can make a significant difference in how families respond, plan, and care for a loved one.
About Carefull
Carefull is the first financial safety platform designed to protect aging adults and their families, from elder fraud, scams, and money mistakes. Built to support the unique needs of older adults, Carefull's proprietary AI provides 24/7 account monitoring, a suite of identity and home protections, along with expert resources to help families, advisors, and financial institutions safeguard families' financial well-being. Banks, credit unions, and wealth advisors use Carefull to deepen relationships across generations, provide proactive protection, and enhance trust with clients navigating both aging and financial caregiving for older adults. Recognized for its innovation in financial safety, Carefull partners with leading institutions to put financial care into financial services. Learn more at GetCarefull.com.
About the Alzheimer's Association
The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
Financing to provide $11.5 million in upfront proceeds with up to an additional $10.4 million of proceeds assuming exercise in full of the warrants Financing priced at a premium to last close SOUTH SAN FRANCISCO, Calif., June 12, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX) ("Quince" or the "Company"), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants ("Warrants") that is expected to result in approximately $11.5 million in upfront proceeds and potential additional proceeds of up to $10.4 million if the accompanying common warrants are exercised in full for cash, before deducting placement agent fees and other private placement expenses. The private placement is being led by healthcare-focused institutional investor Nantahala Capital with participation from existing Quince stockholders including ADAR1 Capital Management, along with members of Quince's senior management. Quince intends to use the net proceeds of this offering for working capital and general corporate purposes, including funding the ongoing enrollment of the Company's pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in Ataxia-Telangiectasia (A-T), research and development expenses, general and administrative expenses and capital expenditures. The net upfront proceeds from the private placement, combined with Quince's current cash, cash equivalents, and short-term investments are expected to fund the Company's operations into the second quarter of 2026, or the second half of 2026 if the Warrants are exercised in full for cash. At the closing, the Company will issue to the investors an aggregate of 8,671,928 shares of common stock (or pre-funded warrants in lieu thereof), along with accompanying Warrants to purchase an aggregate of 8,671,928 shares of common stock (or pre-funded warrants in lieu thereof), at a combined purchase price of $1.325 per share (or $1.324 per pre-funded warrant) and accompanying Warrant (representing a 10% premium over the $1.20 closing price per share of the Company's common stock). The accompanying Warrants have an exercise price of $1.20 per share and will become exercisable immediately. The Warrants will expire five years from the date of issuance. The private placement is expected to close during the week of June 16, 2025, subject to the satisfaction of customary closing conditions. Citizens Capital Markets is acting as the lead placement agent for the private placement. Maxim Group LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC, are acting as co-placement agents for the private placement. The securities to be issued in connection with the private placement described above are being offered in a private placement and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state or other applicable jurisdictions' securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit Forward-looking Statements Statements made in this news release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this news release regarding the expected closing of the private placement; the receipt of additional gross proceeds if the accompanying common warrants are exercised in full; the achievement of positive clinical trial results and approval of the eDSP by the FDA; the company's intended use of the proceeds from the private placement; the company's expectation that the net proceeds from the closing of the private placement, combined with its current cash, cash equivalents and marketable securities, will fund its operating and capital expenditures into the second quarter of 2026, or the second half of 2026, assuming all warrants are exercised for cash; and the company's strategy, future operations, future financial position, projected expenses, expected timing and results of clinical trials, prospects, plans and objectives of management constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks and uncertainties related to: cost, timing, progress and results of the pivotal Phase 3 NEAT clinical trial in A-T indication and potential future trials in other indications; the company's ability to obtain FDA approval and successfully commercialize its product candidate; the satisfaction of customary closing conditions related to the proposed private placement and the impact of general economic, industry or political conditions in the United States or internationally, the current or evolving effects of macroeconomic conditions, on Quince's business operations and activities. There can be no assurance that the company will be able to complete the proposed private placement on acceptable terms, or at all. Quince's actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of Quince's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of its Quarterly Reports on Form 10-Q and in the company's other filings with the SEC. Quince undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as required by law. View source version on Contacts Media & Investor Contact: Stacy RoughanQuince Therapeutics, President, Corporate Communications & Investor Relationsir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
US lawmakers pass tougher penalties for fentanyl traffickers
The US Congress on Thursday passed a bill imposing harsher penalties on fentanyl traffickers, with lawmakers from both parties anxious to crack down on an opioid that has driven an epidemic of deadly overdoses. The Senate-passed bill -- which delivers on a key election pledge of President Donald Trump to get tough on drug smuggling -- was rubber-stamped by the House on a 321-104 vote, with Democrats providing all but one of the no votes. The Justice Department says 75,000 Americans die each year because of fentanyl, making it the number one cause of death for people between the ages of 18 and 34 in the United States. The synthetic opioid is more potent than heroin and much cheaper to produce. "More Americans die of drug overdoses each year than the number of Americans who died in the entirety of the Vietnam War," Republican Senate Majority Leader John Thune said ahead of the vote. The HALT Fentanyl Act places copycat variations of fentanyl -- often sold by traffickers -- on the government's list of most dangerous "Schedule 1" drugs alongside the original substance. Lab-created fentanyl alternatives were reclassified to "Schedule 1" on a temporary basis seven years ago but the vote makes the change permanent. Trump has made halting the flow of fentanyl one of his priorities, even announcing it as a justification for import tariffs on Mexico and Canada. But opponents said the new law -- rather than tackling overdoses -- would simply repeat the mistakes of the so-called "War on Drugs." The Leadership Conference on Civil and Human Rights, a coalition of more than 240 US rights organizations, said in a statement the measure would "exacerbate pretrial detention, mass incarceration, and racial disparities in the prison system." "Beginning in the 1980s, draconian drug laws with harsh mandatory minimums and their resulting enforcement under the banner of the 'war on drugs' fueled skyrocketing prison populations," it said. ft/acb
Business Wire
37 minutes ago
- Business Wire
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX) ('Quince' or the 'Company'), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants ('Warrants') that is expected to result in approximately $11.5 million in upfront proceeds and potential additional proceeds of up to $10.4 million if the accompanying common warrants are exercised in full for cash, before deducting placement agent fees and other private placement expenses. The private placement is being led by healthcare-focused institutional investor Nantahala Capital with participation from existing Quince stockholders including ADAR1 Capital Management, along with members of Quince's senior management. Quince intends to use the net proceeds of this offering for working capital and general corporate purposes, including funding the ongoing enrollment of the Company's pivotal Phase 3 NEAT (N eurological E ffects of e DSP on Subjects with A - T; NCT06193200 / IEDAT-04-2022) clinical trial in Ataxia-Telangiectasia (A-T), research and development expenses, general and administrative expenses and capital expenditures. The net upfront proceeds from the private placement, combined with Quince's current cash, cash equivalents, and short-term investments are expected to fund the Company's operations into the second quarter of 2026, or the second half of 2026 if the Warrants are exercised in full for cash. At the closing, the Company will issue to the investors an aggregate of 8,671,928 shares of common stock (or pre-funded warrants in lieu thereof), along with accompanying Warrants to purchase an aggregate of 8,671,928 shares of common stock (or pre-funded warrants in lieu thereof), at a combined purchase price of $1.325 per share (or $1.324 per pre-funded warrant) and accompanying Warrant (representing a 10% premium over the $1.20 closing price per share of the Company's common stock). The accompanying Warrants have an exercise price of $1.20 per share and will become exercisable immediately. The Warrants will expire five years from the date of issuance. The private placement is expected to close during the week of June 16, 2025, subject to the satisfaction of customary closing conditions. Citizens Capital Markets is acting as the lead placement agent for the private placement. Maxim Group LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC, are acting as co-placement agents for the private placement. The securities to be issued in connection with the private placement described above are being offered in a private placement and have not been registered under the Securities Act of 1933, as amended (the 'Securities Act'), or any state or other applicable jurisdictions' securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit Forward-looking Statements Statements made in this news release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this news release regarding the expected closing of the private placement; the receipt of additional gross proceeds if the accompanying common warrants are exercised in full; the achievement of positive clinical trial results and approval of the eDSP by the FDA; the company's intended use of the proceeds from the private placement; the company's expectation that the net proceeds from the closing of the private placement, combined with its current cash, cash equivalents and marketable securities, will fund its operating and capital expenditures into the second quarter of 2026, or the second half of 2026, assuming all warrants are exercised for cash; and the company's strategy, future operations, future financial position, projected expenses, expected timing and results of clinical trials, prospects, plans and objectives of management constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks and uncertainties related to: cost, timing, progress and results of the pivotal Phase 3 NEAT clinical trial in A-T indication and potential future trials in other indications; the company's ability to obtain FDA approval and successfully commercialize its product candidate; the satisfaction of customary closing conditions related to the proposed private placement and the impact of general economic, industry or political conditions in the United States or internationally, the current or evolving effects of macroeconomic conditions, on Quince's business operations and activities. There can be no assurance that the company will be able to complete the proposed private placement on acceptable terms, or at all. Quince's actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of Quince's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of its Quarterly Reports on Form 10-Q and in the company's other filings with the SEC. Quince undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as required by law.
